Status:
ACTIVE_NOT_RECRUITING
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
Lead Sponsor:
University Hospital, Akershus
Collaborating Sponsors:
The Bergesen Foundation
South-Eastern Norway Regional Health Authority
Conditions:
Ataxia Telangiectasia
Eligibility:
All Genders
3+ years
Phase:
PHASE2
Brief Summary
The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.
Detailed Description
Ataxia Telangiectasia (AT) is a genetic disease, where patients are born with mutations in the Ataxia- Telangiectasia Mutated (ATM) gene. The gene codes for the ATM kinase, which is required for repai...
Eligibility Criteria
Inclusion
- clinically and molecular verified classical A-T disease
Exclusion
- less than 2 years of age
- participation in other on-going study
- pregnancy
- liver failure
- other severe medical conditions considered to set patient at risk
Key Trial Info
Start Date :
June 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2027
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04870866
Start Date
June 5 2019
End Date
June 16 2027
Last Update
August 17 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hilde Loge Nilsen
Lørenskog, Norway
2
Oslo University Hospital
Oslo, Norway